Biotech Co.* (Symbol) |
Pharma Co. (Symbol/Country) |
Type/Product Area |
Disclosed Funding (M) |
Terms/Details (Date) |
Adenosine Therapeutics LLC* |
DuPont Pharmaceuticals Co. (NYSE: DD) |
License agreement/coronary vasodilator compounds, ATL-146e and ATL-193 |
ND |
DuPont gains worldwide rights to develop and use the compounds within the heart imaging field for diagnosis and prognosis of coronary artery disease, while Adenosine retains rights in all other fields; DuPont will pay a licensing fee and milestones, provide funding for a three-year research program, and will pay royalties on any resulting products; DuPont will also fund clinical trials and license the data to Adenosine for use in clinical trials in other indications (4/00) |
Adolor Corp. (ADLR) |
Santen Pharmaceutical Co. Ltd. (Japan) |
License and development agreement/topical uses of ADL 2-1294 (loperamide) for the treatment of ophthalmic pain |
ND |
Adolor will receive an up-front payment and may receive milestones and royalties on net sales; the companies have agreed to negotiate an agreement for Adolor to market and sell ADL 2-1294 to hospitals in the U.S.; Santen will be responsible for all development activities (4/00) |
AlphaOne Pharmaceuticals Inc.* |
Baxter Healthcare Corp. (NYSE:BAX) |
License agreement/recombinant alpha-one antitrypsin to treat hereditary emphysema, and possibly other pulmonary indications (4/00) |
ND |
Baxter gains exclusive worldwide marketing and distribution rights for rAAT to treat hereditary emphysema, with an option to develop the product for other pulmonary indications |
Ambion Inc.* |
Abbott Laboratories (NYSE:ABT) |
License agreement/use of armored RNA technology in products and processes for in vitro diagnostics (4/00) |
ND |
Abbott gains non-exclusive worldwide rights (4/00) |
Amersham Pharmacia Biotech (jointly owned by Nycomed Amersham plc [UK; NYSE:NYE] and Pharmacia Corp. [NYSE:PHA]) |
Beckman. Coulter Inc. (NYSE:BEC) |
Research collaboration/development of capillary coatings and matrices to meet requirements of CE in DNA sequencing and fragment analysis applications |
ND |
Extension of ongoing relationship that has been established through efforts on several projects (3/00) |
Amersham Pharmacia Biotech (jointly owned by Nycomed Amersham plc [UK;NYSE:NYE] and Pharmacia Corp. [NYSE: PHA]) |
Novo Nordisk A/S (Denmark) |
Technology agreement/use of Amersham's microarray technology for research into disease and the development of drugs |
ND |
Novo gains rights to use AP Biotech technology to make and use gene expression microarrays (4/00) |
Arena Pharmaceuticals Inc.* |
Eli Lilly and Co. (NYSE: LLY) |
Research collaboration/development of orphan G protein-coupled receptors as drug screening targets, using Arena's CART technology; initial focus on central nervous system, endocrinology and cardiovascular targets |
ND |
Arena will be responsible for receptor identification, localization and regulation, and the application of CART technology to Lilly-selected receptors and validation of screening assays based on those receptors; Arena will receive an up-front fee, research funding, milestones and royalties on resulting products; Lilly will be responsible for screening its chemical compound library using selected CART receptor assays, identification of chemical leads and preclinical and clinical development; Lilly has exclusive worldwide rights to any resulting products (4/00) |
Array BioPharma Inc.* |
Eli Lilly and Co. (NYSE:LLY) |
Research collaboration/chemistry-based collaboration for drug discovery |
ND |
Up to 30 Array scientists will work with Lilly scientists on several drug discovery projects (3/00) |
Astex Technology Ltd.* (UK) |
Janssen Research Foundation (unit of Johnson & Johnson [NYSE:JNJ]) |
Research collaboration/use of Astex's high-throughput X-ray crystallography technology to optimize lead compounds in a drug discovery project |
ND |
ND |
Atugen AG* (Germany) |
Boehringer Ingelheim International GmbH (Germany) |
Research collaboration/use of Atugen's gene target validation services |
ND |
BI will provide Atugen with gene target sequences and specific cell lines; Atugen will provide delivery optimization to the cell lines and develop GeneBloc reagents to inhibit the expression of the target genes (4/00) |
Aurora Biosciences Corp. (ABSC) |
NV Organon (the Netherlands) |
Development collaboration/development of high-throughput drug discovery screening assays for several key molecular target classes, including orphan G protein-coupled receptors, ion channels and enzymes; Organon gains access to aspects of Aurora's ion channel technology platform |
ND |
Aurora will receive an up-front and annual payments for screen development and technology access; Organon will also make milestone and royalty payments for compounds commercialized through the use of the screens; Organon has an option to have Aurora perform screening on Aurora's ultra-high-throughput screening platform (UHTSS) (4/00) |
Aurora Biosciences Corp. (ABSC) |
Wyeth-Ayerst Research (unit of American Home Products Corp. [NYSE: AHP]) |
License agreement/Aurora's green fluorescent protein mutant technology (4/00) |
ND |
Wyeth gains a non-exclusive license to GFP technology internal use in specified genomics technologies and other application, including use in transgenic organisms (4/00) |
Aurora Biosciences Corp. (ABSC) |
The R.W. Johnson Pharmaceutical Research Institute and Janssen Research Foundation (units of Johnson & Johnson [NYSE:JNJ]) |
Development agreement/ion channel assay development and access to Aurora technologies and scientific support |
ND |
ND (5/00) |
Biacore International AB (Sweden) |
Pharmacia Corp. (NYSE: PHA) |
Research collaboration/evaluation of Biacore's new high-performance system in analyzing the serum protein binding of drug candidates |
ND |
Pharmacia will evaluate the system; further details ND (4/00) |
Celera Genomics (NYSE:CRA) |
Takeda Chemical Industries Ltd. |
Database subscription/Five of Celera's genomics databases |
ND |
Five-year subscription that includes access to databases, bioinformatics systems and tools for viewing, browsing and analyzing genomic information (3/00) |
CeNeS Pharmaceuticals plc (UK; LSE:CEN) |
Ares-Serono (Switzerland) |
Research collaboration/use of CeNeS' drug delivery technologies to generate a novel formulation of a new fertility drug in development at Ares-Serono |
ND |
CeNeS will receive research fees and, if the product is successful, CeNeS will also manufacture the formulation at its GMP pharmaceutical plant in Scotland (3/00) |
Chiron Corp. (CHIR) |
Glaxo Wellcome plc (NYSE:GLX) |
License agreement/small-molecule therapeutics against hepatitis C virus |
ND |
Glaxo gains non-exclusive rights to research, develop and market small-molecule HCV therapies under Chiron's HCV patent portfolio (4/00) |
Chrysalis Biotechnology Inc.* |
Abbott Laboratories (NYSE:ABT) |
Option, license and development agreement/Chrysalin, a therapeutic for wound healing and tissue repair |
ND |
Agreement is for worldwide rights; further details ND (4/00) |
Cortex Pharmaceuticals Inc. (OTC BB: CORX) |
Shire Pharmaceuticals Group plc (SHPGY) |
Option agreement/Shire will will evaluate the use of Cortex's Ampakine CX516 to treat attention deficit hyperactivity disorder (4/00) |
$1-plus |
Shire will undertake a placebo-controlled, double-blind trial in ADHD patients; Cortex will receive $1M in an equity investment and cash; Shire has the right to convert option into exclusive worldwide license for Ampakines for ADHD; if Shire exercises the option, it will fund all future developmental costs; Cortex would receive an up-front fee, milestones, research support and royalties on sales (4/00) |
CyDex Inc.* |
Bristol-Myers Squibb Co. (NYSE:BMY) |
License agreement/use of Cydex's captisol sulfobutyl-ether beta-cyclodextrin drug delivery technology to develop a second compound |
ND |
ND (5/00) |
CytRx Corp. (CYTR) |
Undisclosed |
Evaluation agreement/CytRx's gene delivery technology in a gene-based vaccine for HIV |
ND |
Pharma company gains exclusive option to license the technology; CytRx will provide material and consulting services during option period in exchange for certain payments (3/00) |
Elan Corp. plc (Ireland; NYSE: ELN) and Eli Lilly and Co. (NYSE:LLY) |
Wyeth-Ayerst Research (unit of American Home Products Corp. [NYSE:AHP]) |
License agreement/B-amyloid-related diseases, including Alzheimer's disease |
ND |
Wyeth gains a non-exclusive license under the companies' jointly owned patent portfolio; Lilly and Elan retain certain product rights and will receive royalties on products that result from the agreement (4/00) |
Elan Crp. plc (Ireland; NYSE: ELN) |
American Home Products Corp. (NYSE:AHP) |
Development agreement/Elan's 1792 vaccine, to treat and prevent the onset of Alzheimer's disease, plus discovery and characterization of additional products |
ND |
AHP will make an up-front payment and provide milestone payments; AHP and Elan will equally share costs and revenues on all products covered in the collaboration (4/00) |
Genetronics Biomedical Ltd. (AMEX:GEB) |
Undisclosed |
Research collaboration/gene therapy using Genetronics' electroporation technology for gene delivery |
ND |
Agreement is the company's fifth in gene therapy field (4/00) |
Genometrix Inc.* |
Procter & Gamble (NYSE:PG) |
Technology access/Genometrix's GenoVista Partnership Program, which provides access to high-throughput microarray fabrication and hybridization services for genotyping and gene expression profilign; P&G also gains access to the Internet-based VistaLogic Information System |
ND |
ND (4/00) |
Genset (France; GENXY) |
Sanofi-Synthelabo (France) |
Pharmacogenomics collaboration/discovery and analysis of significant polymorphisms in a large number of targets for drug development for an undisclosed central nervous system disease |
ND |
Sanofi-Synthelabo receives an exclusive worldwide license to use the data and clones generated through the collaboration to develop and commercialize drugs for the treatment of undisclosed diseases; Genset will receive research funding, milestones and royalties on resulting products (4/00) |
ICAgen Inc.* |
Yamanouchi Pharmaceutical Co. Ltd. (Japan) |
Research and development collaboration/novel products aimed at several central nervous system disorders |
ND |
ICAgen will receive an up-front payment, research funding and milestones, plus royalties on products; ICAgen also has the right to develop and commercialize products for certain CNS indications and to commercialize products not pursued by Yamanouchi (3/00) |
Kos Pharmaceuticals Inc. (KOSP) |
DuPont Pharmaceuticals Co. (NYSE:DD) |
Development agreement/covers Nicostatin and exploration of additional opportunities in the cardiovascular and cholesterol management areas (5/00) |
$80 |
DuPont will provide funding of up to $80M, consisting of $17.5M in milestones and $32.5M for future clinical development; DuPont will also make an equity investment of up to $30M through FDA approval (companies will share promotion costs equally, and will share profits equally after deducting a royalty to Kos) (5/00) |
Lark Technologies Inc. (OTC BB: LDNA) |
Novartis Research Foundation (unit of Novartis AG [NYSE:NVS]) |
Service agreement/Lark will provide DNA sequencing services to support gene discovery efforts at Novartis |
Novartis will supply biological materials to Lark, which will provide high-throughput DNA sequencing for a fee; financial terms ND (5/00) |
|
Lexicon Genetics Inc. (LEXG) |
American Home Products Corp. (NYSE: AHP) |
Research collaboration/use of Lexicon's OmniBank Internet Universal program to determine the function of genes that represent potential drug targets; agreement includes access to gene database and a knockout mouse library and services, plus an option to access Lexicon's Seek-Target Validation program to determine gene function |
ND |
Multi-year agreement; AHP gains non-exclusive access to products and services in exchange for fees; Lexicon may receive royalties on sales of drugs and diagnostics developed using genes discovered in the OmniBank database; under a separate agreement, Lexicon granted a non-exclusive sublicense to AHP for use of certain aspects of positive-negative selection and isogenic DNA technology in AHP's in-house research programs (4/00) |
Martek Biosciences Corp. (MATK) |
Abbott Laboratories (NYSE:ABT) |
License agreement/use of long-chain polyunsaturated fatty acids in infant formulas |
ND |
Abbott receives a non-exclusive license to the technology in exchange for initial cash payments and royalties on resulting products (4/00) |
MediGene AG* (Germany) |
Schering AG |
Development agreement/MediGene's viral vaccine to treat precancerous lesions of the cervix caused by human papilloma viruses |
US$25 |
Schering received a worldwide exclusive license, with MediGene retaining an option for distribution in countries in which Schering decides not to commercialize; Schering will pay up to $25M in up-front and milestone payments and research funding, plus royalties on any resulting products (3/00) |
Medinox Inc.* |
Fuso Pharmaceutical Industries Ltd. (Japan) |
Development and marketing agreement/NOX-100, Medinox's nitric oxide neutralizing compound for sepsis |
ND |
Fuso gains exclusive rights to develop and market NOX-100 for sepsis and one additional indication in Japan; Fuso made an equity investment and paid an up-front fee, and may pay milestones and royalties; Medinox retains manufacturing rights (5/00) |
Microcide Pharmaceuticals Inc. (MCDE) |
Daiichi Pharmaceutical Co. Ltd. (Japan) |
Research collaboration/discovery and development of inhibitors that will overcome the effect of efflux pumps in Pseudomonas aeruginosa |
ND |
Microcide retains co-promotion rights for North America and will receive milestones and royalties on any resulting products; those products are expected to be used in combination with Daiichi's quinolone antibiotics to increase their effectiveness against gram-negative bacteria (5/00) |
Myriad Genetics Inc. (MYGN) |
Hitachi Ltd. (Japan; NYSE: HIT) |
License agreement/Myriad's ProNet proteomic screening technology; Hitachi will establish a ProNet facility to expedite discovery of protein-protein interactions for Japanese customers |
$26 |
Myriad will receive an up-front license fee of $15M and research funding of $11M over three years (5/00) |
NPS Pharmaceuticals Inc. (NPSP) |
Abbott Laboratories (NYSE:ABT) |
Licensing agreement/NPS-1776, a compound with potential neuroscience applications, plus other compounds |
ND |
Abbott gains exclusive worldwide development and marketing rights and will provide research funding and milestone payments, plus royalties on resulting products (3/00) |
Pharming Group NV (the Netherlands) |
Baxter Healthcare Corp. (NYSE: BAX) |
Research and development collaboration/recombinant human C1 inhibitor to treat hereditary angioedema |
ND |
Baxter gains worldwide marketing rights for the hereditary angioedema indication; development costs will be shared, and Pharming will receive license fees; upon commercialization, a royalty arrangement will be implemented (3/00) |
Protein Design Labs Inc. (PDLI) |
Chugai Pharmaceutical Co. Ltd. (Japan) |
License agreements/PDL's patents for humanization of monoclonal antibodies |
$6.04 |
Chugai signed multiple worldwide, non-exclusive agreements under PDL's antibody humanization patents for an undisclosed number of Chugai antibody targets, including a clinical-stage antibody to the IL-6 receptor for rheumatoid arthritis; Chugai will pay up-front signing and licensing fees of $6.04M, annual maintenance fees and royalties on any sales (5/00) |
Protein Design Labs Inc. (PDLI) |
Toagosei Co. Ltd. (Japan) |
License and joint development agreement/antibody developed by Toagosei and humanzied by PDL; the antibody binds to vascular endothelial growth factor and has potential applications in cancer treatment |
ND |
Under 7/99 agreement, PDL has obtained exclusive development and marketing rights to the antibody in North America and has the first option to obtain exclusive rights elsewhere, with the exception of Japan, where Toagosei has exclusive rights; PDL will direct clinical development and the companies will share development costs and profits from sales in markets outside Japan (5/00) |
Proteome Systems Ltd.* (Australia) |
Shimadzu Corp. (Japan) |
Development collaboration/instruments for the near parallel high-throughput screening of proteins |
ND |
Collaboration will combine Proteom's chemical printing technology with Shimadzu's MALDI mass spectrometry (3/00) |
RxKinetix Inc.* |
Elan Corp. plc (Ireland; NYSE:ELN) |
License and research collaboration/development of compound formulations to treat oral mucositis |
$2.5 |
Alliance takes the form of a structured joint venture into which each company will contribute technology to identify several compounds; initial term is for three years; Elan will make a $2.5M equity investment in RxKinetix and subscribe for a convertible note in the joint venture; R&D will be jointly funded (5/00) |
Sangamo BioSciences Inc (SGMO) |
Bristol-Myers Squibb Co. (NYSE:BMY) |
Research collaboration/use of Sangamo's specific Universal GeneTools in Bristol-Myers' internal programs |
ND |
ND (4/00) |
Sepracor Inc. (SEPR) |
Eli Lilly and Co. (NYSE:LLY) |
License agreement/modified formulation of fluoxetine, an active ingredient found in Prozac |
$90 |
Federal Trade Commission concluded review of collaboration under which Sepracor receives an up-front payment of $20M and up to $70M in additional milestones; Sepracor will also receive royalties; Lilly has exclusive worldwide rights for all indications and uses and will be responsible for developmental work on (R)-fluoxetine for all indications and uses, as well as regulatory submissions, manufacturing, marketing and sales (4/00) |
SkyePharma plc (UK;SKYE) |
Pfizer Inc. (NYSE:PFE) |
Development collaboration/use of SkyePharma's DepoFoam sustained-release technology to formulate an undisclosed Pfizer compound |
ND |
New agreement follows 3/00 feasibility agreement for use of SkyePharma's Geomatrix delivery system 5/00) |
SkyePharma plc (UK;SKYE) |
Merck KGaA (Germany) |
Development collaboration/use of SkyePharma's Geomatrix oral controlled-release technology to formulate a Merck compound |
ND |
Deal follows proof-of-concept testing; SkyePharma will be responsible for scaling up the process, providing materials for clinical trials and assisting Merck in the compilation of regulatory dossie; SkyPharma will handle manufacturing; Merck receives an exclusive worldwide license and will pay all development costs plus royalties on sales; manufacturing revenues and royalties to SkyePharma are projected at 10%-15% of net sales (5/00) |
Symyx Technologies Inc. (SMMX) |
Aventis Research & Technologies GmbH & Co. KG (NYSE: AVE) |
Technology collaboration/development of novel instrumentation for high-throughput analysis of pharmaceutical compounds |
ND |
Companies will share costs under one-year agreement (4/00) |
United Therapeutics Corp. (UTHR) |
Grupo Ferrer Internacional SA (Italy) |
Uniprost, a subcutaneous prostacyclin therapy in Phase III trials for treatment of late-stage pulmonary hypertension |
ND |
Ferrer gains distribution rights for Spain, France, Germany, Italy, Portugal, Greece and Belgium, as well as Mexico and all countries in Latin America (5/00) |
Vertex Pharmaceuticals Inc. (VRTX) |
Novartis Pharma AG (NYSE:NVS) |
Research collaboration/eight small-molecule drugs directed at targets in the kinase protein family (5/00) |
$800 |
Novartis will have exclusive world-wide development, manufacturing and marketing rights; Vertex will receive up to $800M in precommercialization payments if all eight compounds are fully developed; Novartis will make an initial payment of $15M, provide research funding of $200M over six years and will provide further license fees, milestones and reimbursements of up to $600M; Vertex will have responsibility for drug discovery and clinical proof-of-concept testing (5/00) |
Notes: | ||||
# This chart contains information on new agreements, covering the time between 3/16/00 and 5/18/00. It does not include arrangements that are classified strictly as production, manufacturing, marketing and/or distribution and supply agreements. The chart above also does not include any collaborations that involve agricultural product development (which are covered periodically in this publication). | ||||
* Private companies are indicated with an asterisk. | ||||
AMEX = American Stock Exchange; CDNX = Canadian Venture Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; NM = Nouveau Marche; OTC BB = Over The Counter Bulletin Board | ||||
ND = Not disclosed, reported and/or available | ||||
